Abstract
The purpose of this study was to translate and linguistically validate the FACT-EGFRI-18 scale into 22 languages - Arabic, Cebuano, Chinese (Simplified), Chinese (Traditional), French, German, Hebrew, Hungarian, Italian, Japanese, Korean, Malay, Polish, Portuguese, Russian, Romanian, Spanish, Tagalog, Tamil, Thai, Turkish, and Ukrainian for use in Belgium, Brazil, Canada, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia, Philippines, Poland, Portugal, Romania, Russia, Singapore, Spain, Thailand, Turkey, Ukraine, and USA. The FACT-EGFRI-18 was translated based on the FACIT methodology: two forward translations, one reconciled version of the two forward translations, one back-translation into English, independent review, harmonization across languages, formatting and proofreading. Patients completed the FACT-EGFRI-18 questionnaire and participated in cognitive debriefing interviews to assess the relevance, understandability, and appropriateness of the translations. Qualitative analyses of subjects’ comments assessed the linguistic equivalence of each translated version. Total study sample consisted of 214 cancer patients (97 males and 117 females). The mean age of the sample was about 58 years. 199 patients were receiving treatment with EGFR inhibitors at the time of administration. The translated items were well understood by participants in each sample and were revised as needed if participants’ comments revealed misunderstanding of an item’s intended meaning. For example, the terms/phrases “embarrassed,” “irritated,” “skin condition,” “social life,” and “unattractive“ required alternative translation solutions to ensure cultural appropriateness, conceptual equivalence and harmonization in some languages. The FACT-EGFRI-18 has demonstrated linguistic validity across 22 languages. The translations are considered acceptable for PRO assessment in international research and clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
